Guest guest Posted September 2, 2007 Report Share Posted September 2, 2007 I have had BioAlcamid in my face for 6 years with no problems. I do want to get some out and Dr Casavantes in Tijuana does it. Dr in LA showed some slides in a lipodystrophy meeting we had 3 weeks ago where he showed a patient that had an infection in his BioAlcamid "pocket" and he was able to extract all of it easily. Most people on BioAlcamid are doing fine after years, so for those of you who have it and have no problems, just relax. If an infection occurs for any reason, it can be treated with antibiotics and extraction. No other product can be extracted after years, so that is one of the advantanges of this product. However, I really think that Love used to inject too much at one time back in the days. It would be better if BioAlcamid is injected more conservatively in smaller quantities over 3-4 sessions (not one or two) , in my opinion. Regards, Vergelpowerusa dot orgGet a sneak peek of the all-new AOL.com. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 21, 2011 Report Share Posted September 21, 2011 ---------- Forwarded message ----------From: Nevin <brnevin@...>Date: Wed, Sep 21, 2011 at 7:32 PM Subject: Re: Digest Number 3761No Reply <notify-dg- >Hi,I recently suffered my second infection. Someone squeezed my cheek hard. It was the cheek that had not had a previous infection. A doctor took three samples of puss (using a needle) to determine which antibiotic would be needed. Eventually, some puss started coming out through a hole made up near my eye.I was able to squeeze out most of the puss, up and out that hole at the top.I`m told that some product was probably removed too. Ironically, I had an appointement booked, 1 month after the infection began, with Dr. Gantous, here in Toronto.I understand he is the only person in Canada willing to deal with BioAlcamid removal. By the time I saw him, the original reason for my consultation had resolved itself.There had been migration of the product down near my jaw, and it was bulging.The infection caused the product to firm up, and the bulging is gone. During my visit, here is what Dr. Gantous told me: Bioalcamid is not an easy product to extract, or fiddle with.If some is taken out at the lower end of the face, the rest tends to migrate down and then it all has to be removed. Those were his words: it all has to be removed.Yes, I`ve heard it`s impossible to remove it all, but, obviously, he is able to remove a lot of it.He told me that if I was seeking a perfect solution, i`d probably be disappointed. I asked if it was true that scar tissue develops, so that one doesn`t look as gaunt as one did beforehand, if the product were to be removed.He said that to some extent that was true. Anyway, i would never have thought that an infection would have solved my problem of the bulge caused by migration of BioAlcamid.In spite of two horrible infections, I`m glad I got it put in, because I am able to work without worrying about how i look. I was at the point where I would have had to quit my job, and BioAlcamid allowed me to live normally.All that said, if I were making the decision today, the 25% infection rate, 3 years after insertion of product, would deter me. Most reputable surgeons do not use the product any longer. On Wed, Sep 21, 2011 at 4:41 AM, < > wrote: Messages In This Digest (12 Messages) 1a. Re: Non-Invasive Methods Of Penile Lengthening: Fact Or Fiction From: J Barrowster 2. NATAP/ICAAC: Cobicistat Effect on GFR From: Jules Levin 3. NATAP/ICAAC: Anal Dysplasia/Cancer MSM Protocol Effective From: Jules Levin 4a. NATAP/ICAAC: polyacrylamide hydrogel (PHA) injections for HIV-relate From: Jules Levin 4b. Re: NATAP/ICAAC: polyacrylamide hydrogel (PHA) injections for HIV-re From: Vergel 5. The Twilight of the Redhead From: Mark 6. NATAP/ICAAC: Sangamo HIV Gene Therapy From: Jules Levin 7. VL question from labcorp report From: hoppefaith@... 8. Fw: Turning the Tide Together: XIX International AIDS Conference The From: nelsonvergel@... 9a. Fw: TheBodyPRO.com Newsletter: The Latest HIV/AIDS Research and News From: Vergel 10. Fw: Hot Topics at The Body's " Ask the Experts " Forums- Dr Bob died From: Vergel 11. removal of Bio-Alcamid. Fact or fiction? From: K View All Topics | Create New Topic Messages 1a. Re: Non-Invasive Methods Of Penile Lengthening: Fact Or Fiction Posted by: " J Barrowster " barrowster@...  johnftl59 Tue Sep 20, 2011 6:22 am (PDT) Bottom line There are no pills to make a penis grow. There is no reason that any pharmacological agent should specifically lengthen the penis, either. JB Back to top Reply to sender | Reply to group | Reply via web post Messages in this topic (2) 2. NATAP/ICAAC: Cobicistat Effect on GFR Posted by: " Jules Levin " JuLev@...  jules72orange Tue Sep 20, 2011 6:22 am (PDT) > > Subject: NATAP/ICAAC: Cobicistat Effect on GFR > > Effect of Cobicistat on Glomerular Filtration Rate in Subjects with Normal and Impaired Renal Function - see attached full poster report > > > > > > Reported by Jules Levin > > 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17-20, 2011 Chicago, Illinois, USA > > P German, HC Liu, D Warren, M Hepner, J s, BP Kearney, and A Mathias Gilead Sciences Inc., City, CA, USA > > > INTRODUCTION > > • Cobicistat (COBI) is a potent CYP3A inhibitor (pharmacoenhancer) currently in Phase 3 testing as a component of a single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir and with atazanavir for the treatment of HIV-1 infection in treatment-naïve patients > > • In Phase 1 and 2 clinical studies, small increases in serum creatinine and corresponding decreases in estimated creatinine clearance (eGFR, using Cockcroft-Gault method) were observed in subjects receiving COBI > – These changes occurred within the first few days of dosing and resolved upon stopping COBI > – The onset, magnitude and resolution of this effect was consistent with a drug-interaction effect > > • This study evaluated the potential effect of COBI on renal function, comparing eGFR to actual GFR (aGFR) using iohexol, a probe drug excreted by glomerular filtration > > AUTHOR CONCLUSION > > • COBI does not affect true GFR > – No change in aGFR using probe drug iohexol > – No statistically signifi cant changes in aGFR with placebo or RTV > > • COBI alters eGFR secondary to small changes in serum creatinine > – Effects in this study are similar to that observed in previous studies in healthy volunteers and HIV-infected patients > – No changes in eGFR with placebo or RTV > > • Alteration in eGFR but not in aGFR suggests COBI affects proximal tubular secretion of creatinine > – Drugs such as cimetidine, trimethoprim, pyrimethamine, rilpirivine, and dolutegravir have been shown to alter with creatinine secretion1,2,3 > – Mechanistic studies have evaluated COBI inhibition of kidney transporters of creatinine [see poster A1-1724, E-I Lepist, BP Murray, L Tong, et. al. Effect of Cobicistat and Ritonavir on Proximal Renal Tubular Cell Uptake and Effl ux Transporters, ICAAC 2011] > > • COBI exposure was higher in subjects with eGFR 50-79 ml/min than in subjects with eGFR ≥ 80 ml/min in this study > – Mechanism for the higher exposures in subjects with eGFR 50-79 ml/min is unknown > – Similar COBI exposure observed in another study in patients with severe renal impairment and control subjects with normal renal function > • Consistent with renal excretion being a minor pathway (< 10%) for COBI elimination > • Study drugs were well-tolerated > > Back to top Reply to sender | Reply to group | Reply via web post Messages in this topic (1) 3. NATAP/ICAAC: Anal Dysplasia/Cancer MSM Protocol Effective Posted by: " Jules Levin " JuLev@...  jules72orange Tue Sep 20, 2011 8:37 am (PDT) > > Subject: NATAP/ICAAC: Anal Dysplasia/Cancer MSM Protocol Effective > > Predictive Value of Protocol to Spot Anal Dysplasia and Cancer in MSM > > 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, 2011, Chicago > > Mark Mascolini > > A protocol involving human papillomavirus (HPV) genotyping, anal Pap testing, and anoscopic examination in men who have sex with men (MSM) had a positive predictive value around 80% for biopsy-confirmed anal intraepithelial neoplasia (AIN) and carcinoma in situ, according to results of a 114-man study at the University Hospital Virgen de las Nieves in Granada, Spain [1]. More than 90% of men had HPV in the anal mucosa, and high-risk HPV genotypes had a relatively high prevalence. > > AIN and anal cancer pose a considerable threat to HIV-positive MSM. A 2010 prospective study of 446 HIV-positive German MSM, for example, found that 36.5% had low-grade AIN, 35.0% had high-grade AIN, and 2.5% had anal carcinoma [2]. But the role of anal cytology (Pap testing) and HPV testing in screening for anal dysplasia and cancer in this population remains uncertain. A cross-sectional study of 410 Canadian MSM with HIV determined that anal cytology and oncogenic HPV detection had high sensitivity but low specificity for detecting AIN 2+ [3]. > > AIN is characterized by abnormal cells that may precede anal cancer. AIN 1 indicates mild changes in abnormal cells, AIN 2 indicates moderate changes, and AIN 3 indicates severe changes. > > From 2008 through 2010, Spanish clinicians collected anal swab samples from 114 HIV-positive MSM, using one sample to genotype HPV by PCR and one sample for Pap testing. Study participants gave the double samples once a year if testing showed normal mucosal cells and no oncogenic (cancer-causing) HPV. Men gave paired samples every 6 months if they had oncogenic HPV and/or low-grade squamous intraepithelial lesions (LSIL) on two occasions. Study participants had anoscopy if they had (1) oncogenic HPV on two occasions regardless of cytology, (2) LSIL and ASCUS (atypical squamous cells of undetermined significance) on Pap testing, or (3) one sample showing high-grade squamous intraepithelial lesions (HSIL). > > The 114 MSM studied averaged 31 years in age and 9.7 sexual encounters in the past year. Half of the men (52.6%) smoked, and 70.5% reported using condoms. These men were diagnosed with HIV for an average of 50 months, and 61% were taking antiretroviral therapy. The group had a high CD4 nadir, averaging 454 cells. While 22% of these men had been treated for syphilis, 11% had been treated for tuberculosis. > > HPV could be detected in anal mucosa of 104 men (91%). The most prevalent HPV genotypes were 6 (in 13%), 11 (in 13%), 16 (in 26%), 18 (in 15%), 51 (in 15%), and CP6 108 (in 15%). Genotypes 16 and 18 are considered high-risk. Almost three quarters of Pap smears (71%) showed abnormal cells. > > Twenty-six men (25% of those with anal HPV) underwent anoscopy. Biopsy results were graded as carcinoma in situ in 3 men (11.5% of 26), AIN 3 in 1 (3.8%), AIN 2 in 4 (15.4%), and AIN 1 in 9 (34.6%). > > HPV genotyping and Pap test results had high positive predictive values but differed in sensitivity and specificity for biopsy-proved AIN 1, 2, or 3, or carcinoma in situ: > > PCR for HPV genotyping: > Sensitivity: 21.5%, > Specificity: 80% > Positive predictive value: 80% > Negative predictive value: 21% > > Pap testing: > Sensitivity: 87.5% > Specificity: 50% > Positive predictive value: 82.3% > Negative predictive value: 60% > > (Sensitivity is the ability of a test to identify people who have a disease; specificity is the ability of a test to classify people who do not have that disease as negative.) > > The screening protocol cost 320 to 400 Euros per person per year, or about $435 to $545. The investigators argued that this approach is cost-effective because of the high prevalence of oncogenic HPV genotypes and dysplastic lesions in this population, and because two thirds of men with a high suspicion of malignant lesions had biopsy-confirmed anal cancer. The researchers did not conduct a formal cost-effectiveness analysis. > > References > 1. Hidalgo Tenorio C, Rivero M, Jarilla F, et al. Utility and performance of a diagnostic protocol and follow-up to the dysplasia of the anal mucosa of HIV-positive patients men who have sex with men (MSM). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2011. Chicago. Abstract H1-1397. > 2. Kreuter A, Potthoff A, Brockmeyer NH, et al. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol. 2010;162:1269-1277. > 3. Salit IE, Lytwyn A, Raboud J, et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS. 2010;24:1307-1313. > Back to top Reply to sender | Reply to group | Reply via web post Messages in this topic (1) 4a. NATAP/ICAAC: polyacrylamide hydrogel (PHA) injections for HIV-relate Posted by: " Jules Levin " JuLev@...  jules72orange Tue Sep 20, 2011 8:38 am (PDT) > > Subject: NATAP/ICAAC: polyacrylamide hydrogel (PHA) injections for HIV-related facial atrophy > > PHA Better Than PLA for HIV Facial Atrophy at 96 Weeks, But More Painful > > 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, 2011, Chicago > > Mark Mascolini > > Patient satisfaction with polyacrylamide hydrogel (PHA) injections for HIV-related facial atrophy was slightly but significantly greater than with polylactic acid (PLA) injections after 48 and 96 weeks in a randomized open-label trial involving 148 people [1]. Cheek thickness at 96 weeks was significantly greater with PHA than with PLA. But blinded assessment of photographs detected no difference between the two remedies, and PHA injections were more painful than PLA injections. > > In France PLA has been licensed to treat facial atrophy since 2001. ANRS investigators planned this noninferiority trial to compare outcomes with PHA versus PLA. All study participants were at least 18 years old and were taking antiretrovirals. No one had prior injection therapy for facial atrophy, and no one was taking stavudine. Everyone had a CD4 count above 100 and a normal coagulation test. The trial's primary outcome was patient satisfaction at week 48 assessed on a visual analog scale ranging from 0 to 10. > > Median ages in the PLA and PHA groups were 48 and 47, and 96% and 91% were men. CD4 counts averaged 538 in the PLA arm and 528 in the PHA arm. About 90% of study participants had a viral load below 50 copies. In the PLA and PHA groups, the investigators rated lipoatrophy mild in 23% and 28%, moderate in 49% and 43%, and severe in 28% and 29%. > > Median numbers of PLA and PHA injections were 6 and 5. Average injection volume per session averaged 9 mL with PLA and 4 mL with PHA. Ten people in the PLA group and 8 in the PHA group had additional injections after week 48. > > In a last-observation-carried-forward analysis at week 48, average patient satisfaction was significantly greater with PHA than with PLA (7.5 versus 7.1, P = 0.0002). Satisfaction with PHA remained significantly greater at week 96 (6.9 versus 6.7, P = 0.003). However, blinded assessment of lipoatrophy photographs by the researchers at weeks 48 and 96 found no difference in improvement between the two injections (P > 0.99). > > Although average cheek skinfold thickness improvement was greater with PHA than PLA at 48 weeks (+0.8 mm), this difference was not statistically significant (P = 0.21). But at week 96 the greater cheek thickness with PHA persisted and reached statistical significance compared with PLA (+1.2 mm, P = 0.038). Quality of life assessed on the MOS HIV scale did not differ significantly between study arms at week 48 or week 96. > > Mean pain score during injections was significantly higher with PHA than with PLA (4 versus 3, P = 0.001). But the two therapies did not differ in rates of bleeding, hematoma, or vagal nerve malaise during injections. After injections, PLA and PHA did not differ in rates of edema, hematoma, pain, or subcutaneous nodules. > > There were four serious adverse events with PHA (granuloma-like lesions) and none with PLA, but this difference stopped short of statistical significance (P = 0.12). The ANRS investigators suggested, though, that " long-term serious complications at the injection site are a concern with PHA. " > > Reference > 1. Lafaurie M, Dolivo M, Porche R, et al. Polylactic acid (PLA) versus polyacrylamide hydrogel (PHA) injections for the treatment of facial lipoatrophy in HIV-infected patients: results of a randomized controlled trial (ANRS 132 smile) at week 96. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2011. Chicago. Abstract H1-1399a. > Back to top Reply to sender | Reply to group | Reply via web post Messages in this topic (2) 4b. Re: NATAP/ICAAC: polyacrylamide hydrogel (PHA) injections for HIV-re Posted by: " Vergel " Vergel@...  nelsonvergel Tue Sep 20, 2011 3:19 pm (PDT) Do not use this product!! It is no different than BioAlcamid. Wait 4-6 years and see what will happen to these patients. Late onset infections, migration, etc do not show up early. On Tue, Sep 20, 2011 at 9:42 AM, Jules Levin <JuLev@...> wrote: > > > > *Subject: **NATAP/ICAAC: polyacrylamide hydrogel (PHA) injections for > HIV-related facial atrophy* > > *PHA Better Than PLA for HIV Facial Atrophy at 96 Weeks, But More Painful* > > 51st Interscience Conference on Antimicrobial Agents and Chemotherapy > (ICAAC), September 17-20, 2011, Chicago > * > Mark Mascolini* > > Patient satisfaction with polyacrylamide hydrogel (PHA) injections for > HIV-related facial atrophy was slightly but significantly greater than with > polylactic acid (PLA) injections after 48 and 96 weeks in a randomized > open-label trial involving 148 people [1]. Cheek thickness at 96 weeks was > significantly greater with PHA than with PLA. But blinded assessment of > photographs detected no difference between the two remedies, and PHA > injections were more painful than PLA injections. > > In France PLA has been licensed to treat facial atrophy since 2001. ANRS > investigators planned this noninferiority trial to compare outcomes with PHA > versus PLA. All study participants were at least 18 years old and were > taking antiretrovirals. No one had prior injection therapy for facial > atrophy, and no one was taking stavudine. Everyone had a CD4 count above 100 > and a normal coagulation test. The trial's primary outcome was patient > satisfaction at week 48 assessed on a visual analog scale ranging from 0 to > 10. > > Median ages in the PLA and PHA groups were 48 and 47, and 96% and 91% were > men. CD4 counts averaged 538 in the PLA arm and 528 in the PHA arm. About > 90% of study participants had a viral load below 50 copies. In the PLA and > PHA groups, the investigators rated lipoatrophy mild in 23% and 28%, > moderate in 49% and 43%, and severe in 28% and 29%. > > Median numbers of PLA and PHA injections were 6 and 5. Average injection > volume per session averaged 9 mL with PLA and 4 mL with PHA. Ten people in > the PLA group and 8 in the PHA group had additional injections after week > 48. > > In a last-observation-carried-forward analysis at week 48, average patient > satisfaction was significantly greater with PHA than with PLA (7.5 versus > 7.1, *P* = 0.0002). Satisfaction with PHA remained significantly greater > at week 96 (6.9 versus 6.7, *P* = 0.003). However, blinded assessment of > lipoatrophy photographs by the researchers at weeks 48 and 96 found no > difference in improvement between the two injections (*P* > 0.99). > > Although average cheek skinfold thickness improvement was greater with PHA > than PLA at 48 weeks (+0.8 mm), this difference was not statistically > significant (*P* = 0.21). But at week 96 the greater cheek thickness with > PHA persisted and reached statistical significance compared with PLA (+1.2 > mm, *P* = 0.038). Quality of life assessed on the MOS HIV scale did not > differ significantly between study arms at week 48 or week 96. > > Mean pain score during injections was significantly higher with PHA than > with PLA (4 versus 3, *P* = 0.001). But the two therapies did not differ > in rates of bleeding, hematoma, or vagal nerve malaise during injections. > After injections, PLA and PHA did not differ in rates of edema, hematoma, > pain, or subcutaneous nodules. > > There were four serious adverse events with PHA (granuloma-like lesions) > and none with PLA, but this difference stopped short of statistical > significance (*P* = 0.12). The ANRS investigators suggested, though, that > " long-term serious complications at the injection site are a concern with > PHA. " > > *Reference* > 1. Lafaurie M, Dolivo M, Porche R, et al. Polylactic acid (PLA) versus > polyacrylamide hydrogel (PHA) injections for the treatment of facial > lipoatrophy in HIV-infected patients: results of a randomized controlled > trial (ANRS 132 smile) at week 96. 51st Interscience Conference on > Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2011. > Chicago. Abstract H1-1399a. > > > > > -- Regards, Vergel Book link <http://amzn.to/hCzxdA> Back to top Reply to sender | Reply to group | Reply via web post Messages in this topic (2) 5. The Twilight of the Redhead Posted by: " Mark " MarkSKing@...  myfabulousdisease Tue Sep 20, 2011 3:19 pm (PDT) When life (or aging, or HIV) takes something away, sometimes we get the chance to replace it with something better. My latest post: http://marksking.com/my-fabulous-disease/the-twilight-of-the-redhead/ Please be well, Mark Back to top Reply to sender | Reply to group | Reply via web post Messages in this topic (1) 6. NATAP/ICAAC: Sangamo HIV Gene Therapy Posted by: " Jules Levin " JuLev@...  jules72orange Tue Sep 20, 2011 3:19 pm (PDT) > > Subject: NATAP/ICAAC: Sangamo HIV Gene Therapy > > Sangamo HIV Gene Therapy Data Reported at ICAAC Sept 19 2011 > > nextbigfuture.com > > Sangamo BioSciences of Richmond, California, says it has found a way to protect the T cells that > > HIV attacks first, so they can live to fight another day. The approach entails temporarily stopping a patient's antiretroviral therapy and removing T cells carrying the CD4 receptor. This surface protein is the doorway by which the virus gains entry into the cell. The collected T cells are exposed to zinc finger nuclease, an enzyme designed to remove the gene for a coreceptor of CD4 called CCR5. The cells are then reinfused into the patient. Once they're back in the body, the new study shows, the cells persist and travel in the body just like normal T cells. > > Experts unaffiliated with Sangamo and its clinical trials agree that the scientific achievement is impressive, but they question the notion that it could yield a functional cure. > > Sangamo is also exploring the potential of stem-cell modification with City of Hope researchers, but the company does not concede that modified stem cells will be necessary or any better than T cells. " Yes, T cells turn over, " says Geoff Nichol, who joined Sangamo as executive vice president of R & D a few months ago to commercialize the platform, " but there are some very long-lasting subsets that can live for years and years and remember the epitope they came up against. We are feeling bullish about T cells because of our data. " > > Sangamo's news is " certainly scientifically interesting, " observes Warner Greene, director of the Gladstone Institute at the University of California, San Francisco. But, he points out, no cell therapy, whether it involves T cells or stem cells, is a practical approach to treating HIV/AIDS throughout the developing world, where seven out of 10 new infections are occurring. " We really need to be looking for therapies that can benefit the millions of individuals with HIV, not just a select few who might be able to afford cellular therapies. " > > Sangamo's approach is based on the observation that some people have a naturally occurring mutation in the CCR5 gene that protects them against HIV. Ordinarily, humans have two copies of every gene. It turns out that individuals with a mutation in both copies of the CCR5 gene cannot be infected by the most common HIV strains. In people with the so-called Delta-32 mutation in just one copy of the gene, infection rarely progresses to AIDS. In the U.S., about 1 percent of the population is thought to carry the helpful mutation, which some researchers believe arose as protection against the Black Death. > > Previous evidence existed showing that CCR5-negative cells could help AIDS patients. In 2007, an American man with AIDS and lymphoma received, as treatment for the cancer, a bone-marrow transplant from a person with the CCR5 mutation. The marrow recipient has been free of both AIDS and cancer since then. Sangamo's method treats a patient's own cells, with less risk than a marrow transplant. > > ------------------------------ > " Functional Cure " For HIV/AIDS Glimpsed In Small Trial, Sangamo is still a long way from proving that SB-728 is safe and effective. > > medicalnewstoday.com > > Researchers testing a potential new gene therapy for HIV/AIDS say they are excited by early results that represent significant progress towards a " functional cure " for the disease. They have presented the data from the phase 1 clinical programs to develop the treatment known as SB-728-T, from Sangamo BioSciences, Inc. of Richmond, California, at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which is being held in Chicago this week, from 17 to 20 September Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 23, 2011 Report Share Posted September 23, 2011 Whats the deal with 25% infection rate with BA? Is this an accurate #? I;ve had BA for about 10 years, courtesy of the fabulous Love and Dr. C. What should a 10 yr BA person be doing now? Would something as simple as a injection like novacaine./lydocaine for a crown, or filling cause a BA implant to burst? What would we take for protection for dental work? Would 10 yrs of no infection offer some protection? I know I;ve had several dental injections for crowns, filings ,etc . with no ill effect. Should I be more pro-active from now on? Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.